Want to see AU:PYC full AI Analyst Report?
Top Page
PYC Therapeutics Limited
(Sydney:PYC)
Select Model
Select Model
Rating:51Neutral
Price Target:
AU$1.50
▲(17.19% Upside)
Action:Reiterated
Date:11/25/25
PYC Therapeutics Limited's stock score is primarily impacted by its financial challenges, including declining revenues and persistent losses. While technical analysis indicates a positive trend, the valuation remains unattractive due to a negative P/E ratio and no dividend yield. The lack of earnings call data and corporate events further limits the assessment.
Positive Factors
Low leverage / balance sheet strength
Minimal leverage reduces bankruptcy and refinancing risk for a cash-burning clinical biotech, giving management structural flexibility to fund R&D and clinical programs through equity or partnerships rather than high interest debt. This preserves optionality across 2-6 months and supports execution of development milestones.
Negative Factors
Declining revenue trend
A persistent revenue decline weakens the firm’s ability to demonstrate commercial traction or license value for RNA programs. Over a multi-month horizon this reduces internal funding capacity, hampers scalability of R&D investment, and makes partnership or financing deals harder and potentially more dilutive.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / balance sheet strength
Minimal leverage reduces bankruptcy and refinancing risk for a cash-burning clinical biotech, giving management structural flexibility to fund R&D and clinical programs through equity or partnerships rather than high interest debt. This preserves optionality across 2-6 months and supports execution of development milestones.
Read all positive factors
PYC Therapeutics Limited (PYC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$1.58B
Dividend YieldN/A
Average Volume (3M)499.42K
Price to Earnings (P/E)―
Beta (1Y)1.64
Revenue GrowthN/A
EPS Growth22.52%
CountryAU
Employees37
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding983,510,440
10 Day Avg. Volume237,599
30 Day Avg. Volume499,416
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)3.84
Price to Sales (P/S)27.69
P/FCF Ratio-12.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.84Price Target Upside121.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)AU$5.00M
PYC Therapeutics Limited Business Overview & Revenue Model
Company Description
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical tr...
How the Company Makes Money
null...
PYC Therapeutics Limited Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.66M | 23.49M | 22.06M | 15.81M | 16.04M | 3.07M |
| Gross Profit | 11.35M | 23.49M | 22.06M | 14.92M | 15.20M | 2.45M |
| EBITDA | -59.80M | -52.88M | -54.55M | -38.25M | -29.39M | -21.04M |
| Net Income | -47.56M | -50.30M | -37.73M | -22.79M | -13.86M | -17.77M |
Balance Sheet | ||||||
| Total Assets | 159.13M | 183.28M | 91.24M | 37.17M | 45.35M | 57.94M |
| Cash, Cash Equivalents and Short-Term Investments | 120.69M | 153.05M | 66.87M | 15.57M | 29.11M | 51.50M |
| Total Debt | 1.26M | 1.02M | 1.11M | 315.49K | 943.77K | 730.35K |
| Total Liabilities | 11.80M | 13.27M | 10.18M | 8.72M | 5.15M | 4.02M |
| Stockholders Equity | 147.18M | 169.57M | 80.50M | 27.75M | 39.35M | 53.04M |
Cash Flow | ||||||
| Free Cash Flow | -66.22M | -52.54M | -38.90M | -24.91M | -22.17M | -12.38M |
| Operating Cash Flow | -65.75M | -51.56M | -38.59M | -24.42M | -21.78M | -11.79M |
| Investing Cash Flow | -463.80K | -975.40K | -307.04K | -477.12K | 32.68M | -15.52M |
| Financing Cash Flow | 138.63M | 138.66M | 90.19M | 11.44M | -182.36K | 38.56M |
PYC Therapeutics Limited Technical Analysis
Positive
1.28
Price Trends
1.43
Positive
1.36
Positive
1.38
Positive
Market Momentum
0.05
Positive
59.22
Neutral
77.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PYC, the sentiment is Positive. The current price of 1.28 is below the 20-day moving average (MA) of 1.58, below the 50-day MA of 1.43, and below the 200-day MA of 1.38, indicating a bullish trend. The MACD of 0.05 indicates Positive momentum. The RSI at 59.22 is Neutral, neither overbought nor oversold. The STOCH value of 77.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:PYC.
PYC Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$2.15B | 70.13 | 9.20% | ― | -69.69% | -78.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$1.58B | -18.46 | -30.03% | ― | ― | 22.52% | |
49 Neutral | AU$338.71M | -92.86 | -15.96% | ― | 364.97% | 74.58% | |
46 Neutral | AU$865.55M | -8.04 | -59.59% | ― | ― | -70.72% | |
41 Neutral | AU$113.80M | -3.18 | 279.21% | ― | ― | -37.23% |
* Healthcare Sector Average
AU:PYC
PYC Therapeutics Limited
1.62
0.23
16.52%
AU:NEU
Neuren Pharmaceuticals Limited
16.95
1.20
7.62%
AU:SPL
Starpharma Holdings Limited
0.71
0.61
631.96%
AU:CU6
Clarity Pharmaceuticals Ltd.
2.32
-1.87
-44.63%
AU:RCE
Recce Pharmaceuticals Ltd.
0.36
0.00
0.00%
PYC Therapeutics Limited Corporate Events
PYC Therapeutics Gains Safety Clearance to Escalate Dosing in PKD Trial
Jul 21, 2026
PYC Therapeutics has received Safety Review Committee clearance to escalate dosing of its Polycystic Kidney Disease drug candidate PYC-003 to 2.4 mg/kg in an ongoing Phase 1b multiple ascending dose study. The decision follows review of safety and...
PYC Therapeutics Secures Shareholder Approval at Extraordinary General Meeting
Jul 15, 2026
PYC Therapeutics Limited announced that all resolutions put to shareholders at its Extraordinary General Meeting on 15 July 2026 were passed following a poll. The meeting considered resolutions outlined in a notice dated 12 June 2026, and the comp...
PYC Therapeutics Wins Long-Term U.S. Patents for Lead RNA Drug Candidates
Jul 7, 2026
PYC Therapeutics has secured key U.S. composition of matter patents for its three clinical-stage RNA drug candidates, covering therapies for Polycystic Kidney Disease, Autosomal Dominant Optic Atrophy and Retinitis Pigmentosa Type 11. The grants e...
PYC Therapeutics Strengthens Financial Leadership with New CFO Appointment
Jul 6, 2026
PYC Therapeutics has appointed Thomas Ulmer as its new chief financial officer, adding a seasoned finance executive with two decades of international leadership experience across biotechnology, pharmaceuticals and healthcare. Ulmer previously serv...
PYC Therapeutics Announces Lapse of 700,000 Unlisted Options
Jun 17, 2026
PYC Therapeutics Limited has reported the lapse of 700,000 unlisted options, comprising 400,000 options exercisable at $3.00 expiring in November 2028 and 300,000 options exercisable at $2.52 expiring in January 2029. The options ceased to exist o...
PYC Therapeutics Resets CEO Pay to Sharpen Market Alignment and Performance Focus
May 26, 2026
PYC Therapeutics has revised the remuneration package for its Chief Executive Officer, Dr. Rohan Hockings, following an independent review aimed at aligning pay with market practices and reflecting the CEO’s role in building long-term shareh...
PYC Therapeutics outlines limits of data and risk profile in investor update
May 22, 2026
PYC Therapeutics has released an investor presentation intended to update shareholders on its business and development pipeline, while stressing that the slides are only an aid and must be read alongside its formal market announcements. The compan...
PYC Therapeutics Cuts Option Overhang as Multiple Incentive Securities Lapse
May 11, 2026
PYC Therapeutics Limited has reported the cessation of several tranches of employee and incentive options listed on the ASX, with exercise prices primarily at $1.70 and one at $0.90. These options, expiring between 2026 and 2031, have either lapse...
PYC to unveil early clinical data on first-in-class gene-targeted eye drugs at ARVO
May 3, 2026
PYC Therapeutics will showcase data from its Phase 1/2 clinical trials for two lead ophthalmology candidates, VP-001 for Retinitis Pigmentosa type 11 and PYC-001 for Autosomal Dominant Optic Atrophy, at the ARVO conference in Denver from 3 to 7 Ma...
PYC Therapeutics Issues New Shares Following Option Exercise and Lodges Cleansing Notice
Apr 28, 2026
PYC Therapeutics has issued 250,000 fully paid ordinary shares following the exercise of an equivalent number of unlisted options priced at $0.90 each, with an expiry date in October 2027. The new shares are being quoted on the ASX, modestly incre...
PYC Therapeutics Lists Additional 250,000 Shares on ASX
Apr 28, 2026
PYC Therapeutics has applied for quotation on the ASX of 250,000 new ordinary fully paid shares, with an issue date of April 28, 2026. The additional securities, arising from the exercise or conversion of existing instruments, will modestly expand...
PYC Therapeutics Advances Genetic Disease Pipeline After $600m Capital Raise
Apr 27, 2026
PYC Therapeutics reported significant first-quarter 2026 progress across its precision medicine pipeline for genetic diseases with no existing treatments. The company advanced all four development programs toward near-term goals, underscoring its ...
PYC Wins EMA Orphan Status for RP11 Gene Therapy Candidate VP-001
Apr 27, 2026
PYC Therapeutics has secured Orphan Drug Designation from the European Medicines Agency for VP-001, its investigational therapy for Retinitis Pigmentosa type 11, a rare blinding eye disease with no approved treatments. The status provides 10 years...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.